



sonova
HEAR THE WORLD

18 May 2026

Full Year Results 2025/26

Eric Bernard, CEO
Elodie Carr-Cingari, CFO

Disclaimer

This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonova's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

This presentation constitutes neither an offer to sell nor a solicitation to buy any securities. This presentation does not constitute an offering prospectus within the meaning of Article 652a of the Swiss Code of Obligations nor a listing prospectus within the meaning of the listing rules of SIX Swiss Exchange.

Sonova name, products names and logos are registered trademarks of Sonova.

Sennheiser™ is a registered trademark of Sennheiser electronic GmbH & Co. KG used under license by Sonova.

Business review

Strong results and continued outperformance – Fully delivering on guidance

Hearing Instruments segment – Strong growth and acceleration in 2HY

- **Very strong development in Wholesale**, led by Ultra and Virto R, driving **double-digit growth in 2HY** and highest YOY market share gain in six years
- **Robust growth in Retail**, fueled by consistent execution and the success of growth initiatives – sequentially **higher growth momentum in 4Q**

Cochlear Implants segment – Continued headwinds

- **Challenges related to VBP** in China, lower upgrades reflecting product cycle and increased competitive pressure in 2HY

Significant improvement in profitability from operating leverage

- Normalized **EBITA margin up +240bps** in LC, supported by strong operating leverage

Targeting above-market sales growth and increased profitability in FY 26/27

- Sales expected to increase by 5%-8%, and core EBIT by 7%-10% at constant currencies



A CHF 6 billion revenue ambition

Powered by

Strategic priorities



Innovate for adoption

- **Design beyond RIC**
- **AI & digitalization** beyond products
- Leverage **synergies** between **hearing aids** and **cochlear implants**
- **"Made for Asia"** solutions



Multi-channel, multi-brand

- **Country-by-country**
- Unlocking **Wholesale – Retail synergies**
- **Connecting consumer insights** with innovation and delivery
- **Retail geo-targeted expansion**



Excel in operations

- Elevate **service** and **customer experience** as a **differentiator**
- Improve **productivity** with optimization of **footprint, automation, and supply** flows



Enablers

Innovation across Technology, Design and Business models

Empowerment

Entrepreneurship

Transparency

Accountability

Collaboration

HI segment – Substantial market share gains and uplift in LC profitability

Sales

CHF 3,353.8m

+7.5% in LC
(2HY: +7.9% in LC)
+6.9% organic growth

EBITA (normalized)

CHF 793.7m

+20.6% in LC
Margin: 23.7%
Margin YOY: +280bps in LC



Segment sales

- || Sales up **+7.5% in LC**, more than twice the estimated market growth
- || **Acceleration in 2HY** against a strong YOY comparison base

Segment profitability

- || **LC margin expansion of +280bps**, reflecting higher sales and benefits from prior year structural cost initiatives in the Retail business

Note: normalized refers to figures before special items but after restructuring cost; for details, please refer to the Appendix growth rates and FY 25/26 figures based on continuing operations

Wholesale business – Successful product launches driving acceleration

Sales

CHF 1,861.8m

+9.5% in LC
(2HY: +10.9% in LC)



- || Substantial LC sales growth of +9.5% in LC, driven by higher volumes and ASP uplift, resulting in highest YOY market share gain in 6 years
- || Growth in 2HY accelerating to +10.9% in LC, reflecting success of Infinio Ultra launch and a strong market reception of Virto R
- || Strong product pipeline and new platform expected to drive continued growth in FY 26/27, building on Sonova's clear leadership in AI-enabled hearing performance



Very positive impact from recent innovations and exciting upcoming launches

Functionality

Sphere™

Direct speech extraction with proprietary DNN chip through real-time AI.



Design

Virto™ R

Smallest size using AI-driven RightFit™ customization.



Usability

EasyGuard™

Sealed dome for easier wax protection and up to 38% reduced service requirements.



Next wave innovation

More compact form factors with real-time AI



More aesthetic, lifestyle-aligned solutions



AI functionalities expansion beyond speech-in-noise

Upcoming launches

New hearing aid platform building on AI leadership



New connectivity solutions with expanded functional

Retail business – Robust organic growth & strong operating leverage

Sales

CHF 1,491.9m

+5.1% in LC
(2HY: +4.4% in LC)
+3.8% organic growth



- || **Exceeding market dynamics**, largely driven by healthy organic growth – sequentially **higher growth momentum in 4Q** – with **modest contribution from bolt-on acquisitions**
- || **Positive consumer response to product launches** through coordinated launch campaign with Wholesale
- || **Significant operating leverage**, driven by structural initiatives executed in FY 24/25
- || Next steps: Deployment of **new AI tools to drive productivity and elevate consumer journey**



CI segment – Continued headwinds in China

New processor in 2HY 26/27

Sales

CHF 252.1m

-11.1% in LC
(-3.8% excl. China)

EBITA (normalized)

CHF 17.2m

-54.8% in LC
Margin: 6.8%
Margin YOY: -560bps in LC

System sales

CHF 179.6m

-10.3% in LC
(+0.7% excl. China)

Upgrade sales

CHF 72.5m

-13.1% vs. PY in LC



Cochlear implant systems

- || Flat sales outside China, despite competitive product launch
- || Challenges from VBP introduction in China

Upgrades and accessories

- || Pressure reflecting product cycle

Segment profitability

- || Impacted by lower sales, partly offset by strict cost control and weaker USD

Planned processor launch in 2HY 26/27*

- || Leveraging Phonak technology and expected to trigger momentum improvement

Note: norm. refers to figures normalized figures before special items but after restructuring cost; for details, please refer to the Appendix

Note: *subject to regulatory approvals

Our sustainability activities align with our vision

Our ambition is to
improve 30 million lives by FY 30/31



Recognitions



Ranked 98th percentile in health care equipment & supplies industry



Prime – B, Top 2% in health care equipment & supplies industry



Gold medal – Top 5%
Score 78/100 *



B score on Climate

Highlights FY 25/26

100%

Of Sonova's operations powered by renewable electricity

>4,800

Employees engaged through Global Learning Week

>81%


Of direct material spent suppliers assessed through Ecovadis

>97%

Of employees completing the Code of Conduct training.

Financial information

Sales development – All regions contributing to growth



Growth components: +5.4% +0.5% +5.9% -6.1% -0.2%

Note: restated refers to comparative information restated for discontinued operations


Growing in all key regions

- **EMEA (+4.8% in LC):** Sustained market share gains along with Retail bolt-ons mainly DE, IT and FR
- **USA (+9.1% in LC):** Share gains in Wholesale in the commercial market and in the VA
- **Americas excl. USA (+7.1% in LC):** Strong growth in Wholesale and Retail bolt-ons in CA and BR
- **APAC (+1.4% in LC):** Robust sales growth in Wholesale and Retail in AU and JP; double-digit Retail growth in CN; continued headwinds from VBP introduction in CN in CI

Impact from FX translation

- Average USD FX down -9.4% vs. CHF in FY 25/26, accounting for more than half of the headwind

Gross profit – 2HY improvement of 40bps resulting in stable margin for the year




Margin development driven by:

- Higher volume and positive ASP development in both the Wholesale and Retail business
- Temporary ramp-up and regionalization costs in 1HY from footprint optimization delivering sustainable improvements in 2HY

Note: normalized refers to figures before special items but after restructuring cost; for details, please refer to the Appendix; restated refers to comparative information restated for discontinued operations

Disciplined OPEX management resulting in substantial operating leverage




|| OPEX up +1.1% vs. sales growth of +5.9% in LC

- || **R&D:** +3.8% in LC, reflecting sustained high level of investments to drive innovation
- || **S&M:** +1.5% in LC, with continued investments in lead generation in Retail
- || **G&A:** +0.2% in LC, supported by disciplined cost management and savings from structural initiatives

Note: normalized refers to figures before special items but after restructuring cost; for details, please refer to the Appendix; restated refers to comparative information restated for discontinued operations

Strong EBITA margin improvement in LC partly offset by FX translation



▮ **Operational margin improvement**, driven by significant operating leverage

▮ **Normalizations** mainly related to 1HY legal settlement, reassessment of legacy product liability provision in CI and impairment of software assets

Key financials – Above-market sales growth and healthy earnings development

	FY 25/26		Δ % in LC	Δ margin in LC
	CHF m	Margin		
Sales	3,605.9		+5.9%	
Gross profit	2,658.3	73.7%	+5.8%	-10bps
OPEX (norm.)	-1,847.1		+1.1%	
EBITA (norm.)	811.2	22.5%	+17.3%	+240bps
Normalizations	-87.1			
EBITA (reported)	724.2	20.1%	+7.7%	+30bps
EBIT (reported)	675.8	18.7%	+7.9%	+40bps
Financial result	-34.1			
Tax	-95.7			
Income after taxes (reported)	546.0	15.1%	+13.9%	+120bps
EPS (norm. in CHF)	10.42		+16.0%	
EPS (reported in CHF)	9.02		+13.6%	

Note: norm. refers to figures normalized figures before special items but after restructuring cost; for details, please refer to the Appendix; growth rates and FY 25/26 figures based on continuing operations

- || Strong sales growth for the Group, driven by substantial share gains in the Hearing Instruments segment
- || Gross profit margin stable in LC with 2HY improvement offsetting temporary ramp-up and regionalization costs
- || OPEX (norm.) up +1.1% in LC, reflecting disciplined cost control and benefits from structural cost initiatives
- || EBITA margin (norm.) +240bps in LC, driven by significant operating leverage
- || Healthy growth in EPS (norm.), up by +16.0% in LC
- || Dividend of CHF 4.70 proposed, highest in the company's history
 - || Up by +7% YOY in CHF
 - || Implying payout ratio of 45%

Pro-forma results within guidance – Planned divestment lifting growth and margin

	FY 25/26		FY 24/25
	CHF m	Δ % in LC	CHF m
Sales from continued operations	3,605.9	+5.9%	3,612.9
Sales Consumer Hearing	233.2	-1.2%	252.5
Sales incl. Consumer Hearing	3,839.1	+5.5%	3,865.4
EBITA (norm.) from continued operations	811.2	+17.3%	782.1
EBITA (norm.) Consumer Hearing	-35.8		-18.6
EBITA (norm.) incl. Consumer Hearing	775.4	+14.5%	763.6

Note: norm. refers to figures normalized figures

- ||• **Pro-forma growth**, including the Consumer Hearing business, well within the guidance range provided for FY 25/26 with sales up +5.5% in LC and normalized EBITA growth of +14.5% in LC
- ||• **Margin from continued operations +230bps** above pro-forma result including Consumer Hearing business
- ||• **Normalized EBITA loss of Consumer Hearing** in FY 25/26 includes cost for one-time reassessment of inventory and tariffs

Cash flow – Continued strong cash conversion of >90%

	FY 25/26		FY 24/25
	CHF m	Δ % in CHF	CHF m
Income before taxes	641.7	-6.2%	684.3
Depreciation & amortization	260.3	+11.9%	232.6
Working capital	-65.1	-0.4%	-65.4
Other cash effects	-24.9	n/m	14.2
Tax paid	-132.9	+34.5%	-98.8
Financial result	55.6	+136.8%	23.5
Operating cash flow	734.5	-7.1%	790.3
Payments for lease liabilities	-78.8	-0.1%	-78.8
Capex	-102.0	-21.5%	-130.1
Other movements in financial assets	-34.6	n/m	0.3
Operating free cash flow	519.1	-10.8%	581.7
Net M&A	-45.5	-36.7%	-71.9
Free cash flow	473.7	-7.1%	509.8
Cash flow from financing activities	-451.3	+12.9%	-399.7

Note: restated for discontinued operations

- || **Operating free cash flow:** Development largely driven by FX translation impact and phasing of tax payments
- || **Cash conversion:** Remains strong at >90%
- || **M&A:** Modest level of Retail bolt-on acquisitions, mainly in DE, CA, the US, AU and BR with cash-out of CHF 45.5m
- || **Cash flow from financing:** Reflecting dividend payment, repayment of lease liabilities and new financing arrangement

Disciplined balance sheet and attractive returns

	31 Mar 2026	30 Sep 2025	31 Mar 2025
Days sales outstanding (DSO)	55	50	54
Days payable outstanding (DPO)	60	55	94
Days inventory outstanding (DIO)	164	163	186
Capital employed (CHF m)	3,519.4	3,560.6	3,578.7
ROCE (reported)	19.0%		19.9%
Net debt (CHF m)	994.3	1,319.6	1,102.4
Net debt/EBITDA	1.1x		1.2x

Note: DSO, DPO and DIO calculated on a 360 days basis; net debt/EBITDA ratio calculated based on net debt the end of the period, divided by 12-months rolling reported EBITDA; restated for discontinued operations

- || **Balance sheet metrics:** Improvements in DIO while DSO remain stable – DPO up slightly vs. 1HY 25/26 but down YOY, reflecting timing of payments to suppliers
- || **ROCE at 19.0%:** Attractive return on capital, with development impacted by higher normalizations and FX
- || **Leverage at 1.1x:** Decrease largely attributable to positive free cash flow generation over the past 12 months

Outlook

Outlook FY 26/27

Continued growth momentum and meaningful operating leverage

SALES growth (LC)

5% to 8%

EBIT growth (LC)
(Core)

7% to 10%

Mid-term target

5% to 10%

Mid-term target

7% to 12%

Market outlook

- Global hearing care market expected to increase by 2-4%, improving toward the mid-term assumption of 3-5%

Wholesale business

- Strong product pipeline and **new platform** to drive growth, building on Sonova's clear leadership in AI-enabled hearing performance

Retail business

- Robust organic growth**, supported by M&A and step-up in new store openings

Cochlear Implants business

- Continued headwinds in 1HY, with an **anticipated pick-up in the 2HY**, following the planned processor launch

Assumptions for modeling purposes

- Reflecting early May 2026 FX, sales growth in CHF is expected to be reduced by 1-2 %-pts and core EBIT growth in CHF by 2-3 %-pts points in FY 25/26
- Non-core items (incl. restructuring costs) expected at around CHF 35–40m

Q&A

Appendix

Disciplined capital allocation supporting growth and shareholder returns

1 Organic growth investments

- || Step-up **R&D** to accelerate roadmap
- || Invest >1% of sales in **digital & IT** initiative
- || **CHF 50m** investment program to drive operational efficiency
- || Capex @ 3.5-4.0% of revenue

2 Retail bolt-ons

- || Scaling store footprint: **CHF 80-100m p.a.**

3 Strategic M&A

- || Selective **larger acquisitions** in strategic countries
- || **Technology** acquisitions

4 Attractive dividend

- || Maintain **payout ratio of around 40%**

5 Healthy balance sheet

- || Targeting **net debt/EBITDA ratio of 1.0-1.5x**

6 Share buyback

- || **No buyback foreseen in FY 26/27** due to strong M&A pipeline
- || Review thereafter once leverage target consistently met

Sales by regions and key markets

	FY 25/26		2HY 25/26		1HY 25/26	
	CHF m	Δ % in LC	CHF m	Δ % in LC	CHF m	Δ % in LC
EMEA	1,904.2	+4.8%	1,016.3	+4.1%	887.9	+5.5%
USA	1,093.7	+9.1%	554.0	+9.9%	539.7	+8.2%
Americas (excl. USA)	263.9	+7.1%	139.9	+9.5%	124.0	+4.7%
Asia / Pacific	344.1	+1.4%	177.0	+0.6%	167.1	+2.2%
Total Sonova	3,605.9	+5.9%	1,887.2	+5.9%	1,718.7	+6.0%

Performance by business

Wholesale business

	FY 25/26			2HY 25/26			1HY 25/26		
	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC
Sales	1,861.8	+2.2%	+9.5%	981.9	+3.0%	+10.9%	879.9	+1.3%	+7.9%
Δ organic	+172.3	-	+9.5%	+103.5	-	+10.9%	+68.7	-	+7.9%
Δ acquisitions	-	-	-	-	-	-	-	-	-
Δ FX	-131.9	-7.2%	-	-74.9	-7.9%	-	-57.0	-6.6%	-

Retail business

	FY 25/26			2HY 25/26			1HY 25/26		
	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC
Sales	1,491.9	+0.3%	+5.1%	785.4	-0.2%	+4.4%	706.5	+0.8%	+5.8%
Δ organic	+56.8	-	+3.8%	+23.4	-	+3.0%	+33.4	-	+4.8%
Δ acquisitions	+18.7	-	+1.3%	+11.2	-	+1.4%	+7.5	-	+1.1%
Δ FX	-71.1	-4.8%	-	-35.9	-4.6%	-	-35.2	-5.0%	-

Performance by business

Cochlear Implants business

	FY 25/26			2HY 25/26			1HY 25/26		
	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC
Sales	252.1	-17.1%	-11.1%	119.8	-23.4%	-17.1%	132.2	-10.4%	-4.8%
Δ organic	-33.8	-	-11.1%	-26.7	-	-17.1%	-7.1	-	-4.8%
Δ acquisitions	-	-	-	-	-	-	-	-	-
Δ FX	-18.1	-5.9%	-	-9.8	-6.3%	-	-8.3	-5.6%	-

Consumer Hearing business (discontinued operations)

	FY 25/26			2HY 25/26			1HY 25/26		
	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC	CHF m	Δ % in CHF	Δ % in LC
Sales	233.2	-7.6%	-1.2%	136.4	+0.4%	+7.7%	96.8	-17.0%	-11.6%
Δ organic	-3.0	-	-1.2%	+10.5	-	+7.7%	-13.5	-	-11.6%
Δ acquisitions	-	-	-	-	-	-	-	-	-
Δ FX	-16.3	-6.5%	-	-9.9	-7.3%	-	-6.4	-5.5%	-

Key financials – Half-year view

CHF m	FY 25/26	Δ % in LC	Δ % in CHF	2HY 25/26	Δ % in LC	Δ % in CHF	1HY 25/26	Δ % in LC	Δ % in CHF
Sales	3,605.9	+5.9%	-0.2%	1,887.2	+5.9%	-0.5%	1,718.7	+6.0%	+0.1%
Gross profit (norm.)	2,658.3	+5.8%	-1.0%	1,418.0	+6.5%	-0.4%	1,240.3	+5.0%	-1.7%
- Gross profit margin (norm.)	73.7%	-10bps	-60bps	75.1%	+40bps	+10bps	72.2%	-70bps	-130bps
OPEX (norm.)	-1,847.1	+1.1%	-2.9%	-938.4	+1.7%	-2.4%	-908.6	+0.4%	-3.4%
EBITA (norm.)	811.2	+17.3%	+3.7%	479.6	+16.4%	+3.8%	331.7	+18.7%	+3.6%
- EBITA margin (norm.)	22.5%	+240bps	+90bps	25.4%	+240bps	+100bps	19.3%	+230bps	+70bps
EBITA (reported)	724.2	+7.7%	-5.8%	421.1	+5.6%	-6.7%	303.1	+10.6%	-4.4%
EBIT (reported)	675.8	+7.9%	-6.1%	395.9	+5.5%	-7.3%	279.9	+11.4%	-4.4%
Financial result (reported)	-34.1	-3.5%	-4.0%	-5.0	-63.4%	-62.4%	-29.1	+32.5%	+31.1%
Tax (reported)	-95.7	-16.9%	-19.8%	-54.9	-19.0%	-22.7%	-40.8	-13.9%	-15.6%
Profit after taxes (reported)	546.0	+13.9%	-3.4%	335.9	+13.3%	-1.9%	210.0	+14.8%	-5.6%

Note: norm. refers to figures normalized figures before special items but after restructuring cost; for details, please refer to the Appendix; growth rates and figures based on continuing operations

Expense by category excluding acquisition-related amortization

	FY 25/26		FY 24/25
	CHF m	Δ % in LC	CHF m
Research & development (norm.)	-217.7	+3.8%	-214.3
in % of sales	6.0%		5.9%
Sales & marketing (norm.)	-1,287.5	+1.5%	-1,333.2
in % of sales	35.7%		36.9%
General & administration (norm.)	-343.6	+0.2%	-355.0
in % of sales	9.5%		9.8%
Other income/expenses (norm.)	+1.8	n/m	+0.2
Total OPEX (norm.)	-1,847.1	+1.1%	-1,902.2
in % of sales	51.2%		52.7%
Total OPEX (reported)	-1,934.1	+5.0%	-1,916.1
In % of sales	53.6%		53.0%

Note: norm. refers to figures normalized figures before special items but after restructuring cost; for details, please refer to the Appendix; growth rates and figures based on continuing operations

New guidance metric on profitability – Moving to core EBIT

	FY 25/26			FY 24/25		
	FY	2HY	1HY	FY	2HY	1HY
Gross profit (reported)	2,658.3	1,418.0	1,240.3	2,684.4	1,423.2	1,261.2
Normalizations	-	-	-	-	-	-
Gross profit (norm.)	2,658.3	1,418.0	1,240.3	2,684.4	1,423.2	1,261.2
Restructuring costs	+6.5	+3.3	+3.2	+15.2	+8.4	+6.8
Gross profit (core)	2,664.7	1,421.2	1,243.5	2,699.6	1,431.6	1,268.0
EBIT (reported)	675.8	395.9	279.9	719.8	426.9	293.0
Normalizations	+87.1	+58.5	+28.6	+13.8	+10.7	+3.1
EBIT (norm.)	762.9	454.4	308.5	733.6	437.5	296.1
Restructuring costs	+17.2	+9.3	+7.9	+43.9	+30.0	+13.9
EBIT (core)	780.1	463.7	316.4	777.5	467.5	310.0
EPS (reported)	9.02	5.55	3.46	9.37	5.69	3.68
Normalizations	+1.40	+1.01	+0.39	+1.06	+1.00	+0.05
EPS (norm.)	10.42	6.56	3.85	10.43	6.69	3.73
Restructuring costs	+0.24	+0.14	+0.11	+0.67	+0.50	+0.18
EPS (core)	10.66	6.70	3.96	11.10	7.19	3.91

Note: norm. refers to figures normalized figures, based on continuing operations

- ▮ Sonova will continue to **drive strategic initiatives** to elevate operational efficiency, lift profitability and generate investment capacity
- ▮ As of FY 26/27, Sonova provides **guidance on core EBIT**, which excludes restructuring costs and includes acquisition related amortization
- ▮ In addition, **core EBIT** metric continues to exclude special items of a certain magnitude, including transaction and integration costs related to M&A, and litigation costs
- ▮ Core EPS will also consider potential **effects of tax reforms**

Detailed comparative figures available at:
[Financial Report | Sonova International](#)


Non-GAAP adjustments

CHF m	FY 25/26			FY 24/25		
	FY	2HY	1HY	FY	2HY	1HY
Transaction and integration costs (HI segment)	+0.6	+0.3	+0.3	+7.5	+4.4	+3.1
Litigation costs (CI segment)	+28.2	-	+28.2	+6.3	+6.3	-
Reassessment of legacy product liability (CI segment)	+23.6	+23.6	-	-	-	-
Impairment of software (HI segment)	+34.7	+34.7	-	-	-	-
Total normalizations to EBITA	+87.1	+58.5	+28.6	+13.8	+10.7	+3.1
Tax impact from normalizations (affecting profit after tax and EPS)	-7.1	-2.0	-5.1	-3.7	-0.6	-3.1
Impact from tax reforms (affecting profit after tax and EPS)	+3.6	+3.6	-	+49.5	+49.5	-
Restructuring costs (pro memoria)	+17.4	+9.1	+8.3	+44.2	+30.0	+14.2
thereof HI segment	+17.9	+9.7	+8.2	+36.0	+25.9	+10.1
thereof CI segment	-0.5	-0.6	+0.1	+8.2	+4.1	+4.1


Note: positive values indicate a positive impact on the normalized/core vs. the respective reported financial metric and vice versa; based on continuing operations

FX information

Sales currency mix



Cost currency mix



Historic FX rates

	FY 24/25	1H-25/26	2H-25/26	FY-25/26	Δ YOY in %	Spot May-2026
USD	0.89	0.81	0.79	0.80	-9.4%	0.79
EUR	0.95	0.94	0.93	0.93	-2.3%	0.92
GBP	1.13	1.09	1.06	1.08	-4.9%	1.06
CAD	0.64	0.59	0.57	0.58	-8.9%	0.57
AUD	0.58	0.53	0.54	0.53	-8.2%	0.56
BRL	0.16	0.15	0.15	0.15	-5.4%	0.16
JPY 100	0.58	0.56	0.50	0.53	-8.3%	0.50

Key dates

Date	Event
June 16, 2026	AGM
October 1 – November 16, 2026	Quiet period
November 17, 2026	Publication of half-year results 2026/27

Sonova Financial Calendar

Please find the full financial calendar here: <https://www.sonova.com/en/financial-calendar>

Investor relations contacts



Thomas Bernhardsgruetter
Senior Director Investor Relations

☎ +41 58 928 33 44

📱 +41 79 618 28 07

✉ Thomas.Bernhardsgruetter@sonova.com



Olivier Fergg
Investor Relations Analyst

☎ +41 58 928 33 45

✉ Olivier.Fergg@sonova.com



Nicole Jenni
Investor Relations Associate

☎ +41 58 928 33 21

✉ Nicole.Jenni@sonova.com

Sonova Group Headquarters

Laubisrütistrasse 28

CH-8712 Stäfa

Switzerland

ir@sonova.com

Switchboard: +41 58 928 01 01

sonova
HEAR THE WORLD